| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Beam Therapeutics (NASDAQ:BEAM) reported its Q4 earnings results on Tuesday, February 27, 2024 at 06:30 AM.
Here's what investors need to know about the announcement.
Beam Therapeutics beat estimated earnings by 271.0%, reporting an EPS of $1.73 versus an estimate of $-1.01.
Revenue was up $296.15 million from the same period last year.
Last quarter the company beat on EPS by $0.12 which was followed by a 3.0% drop in the share price the next day.
Here's a look at Beam Therapeutics's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -1.34 | -1.42 | -1.34 | -1.33 |
| EPS Actual | -1.22 | -1.08 | -1.33 | -0.54 |
| Revenue Estimate | 17.49M | 18.05M | 14.08M | 12.53M |
| Revenue Actual | 17.19M | 20.12M | 24.21M | 20.04M |
To track all earnings releases for Beam Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: BEAM
